<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733460</url>
  </required_header>
  <id_info>
    <org_study_id>BFPET P-01</org_study_id>
    <nct_id>NCT00733460</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety, Biodistribution and Radiation Dosimetry of BFPET as a Potential Myocardial Perfusion Imaging (MPI) Agent for PET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fluoropharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fluoropharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and dosimetry of BFPET™ will be evaluated in healthy volunteers and Coronary Artery&#xD;
      Disease (CAD) patients , male or female and of age ranging between 20-80 years old.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Procedures:&#xD;
&#xD;
      Visit 1: Screening - Eligibility determination&#xD;
&#xD;
      Visit 2 (within 14 days post screening): Injection of BFPET™ and PET Imaging&#xD;
&#xD;
      Visit 3 (within 24-48 hours post dose): Follow-up Visit&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood pressure. Safety Biodistribution Radiation dosimetry</measure>
    <time_frame>pre-dose, post-dose 0, 1, 5, 15, 30, 60 and 90 minutes, 2 hours, 24-48 hours post-dose and 7 days post-dose.</time_frame>
    <description>Change in vital signs, physical examination, ECG measured within 14 days of screening, immediate pre-dose, post-dose and 24-48 hours post-dose.&#xD;
Change in 12-lead Electrocardiogram measured within 14 days of screening, immediate pre-dose, post-dose and 24-48 hours post-dose.&#xD;
Change in 24-hour Holter (initiated 2 hours pre-dose, continuous for 24 hours, time stop recorded.&#xD;
Change in dosimetry sampling (blood and urine)blood measured at time 0 (immediately following injection), 1,5, 15, 30, 60, 90 minutes.&#xD;
Adverse event assessment immediate post dose, 24-48 hours and 7 days post-dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance characteristics of BFPET as a PET tracer for myocardial imaging.</measure>
    <time_frame>30, 60, 120, and 240 seconds.</time_frame>
    <description>Whole body imaging measures radiation dosimetry at rest and under pharmacologic stress</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>BF-PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BFPET</intervention_name>
    <arm_group_label>BF-PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        NORMAL HEALTHY VOLUNTEERS Inclusion Criteria&#xD;
&#xD;
          1. Subject must provide written informed consent prior to any study related procedures;&#xD;
&#xD;
          2. Subject must be ≥ 20 and ≤ 80 years of age;&#xD;
&#xD;
          3. Subject must have a serum creatinine within the investigational site's normal range.&#xD;
&#xD;
          4. Subject must have liver function tests &lt; 1.5 times the investigational site's normal&#xD;
             range.&#xD;
&#xD;
          5. Subject must have a hematocrit level within 5% of the investigational site's normal&#xD;
             range.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any clinically significant acute or unstable physical or psychological disease based&#xD;
             on medical history or screening physical examination;&#xD;
&#xD;
          2. Any clinically significant abnormality in the screening laboratory tests or ECG;&#xD;
&#xD;
          3. Any exposure to any investigational drugs within four (4) weeks prior to Visit 1;&#xD;
&#xD;
          4. Any exposure to investigational radiopharmaceuticals within four (4) weeks prior to&#xD;
             the date of Visit 1;&#xD;
&#xD;
          5. Any new prescription medications within four (4) weeks of Visit 1;&#xD;
&#xD;
          6. Subject has a Positive (+) Serum Pregnancy Test, or the possibility of pregnancy&#xD;
             cannot be ruled out prior to dosing or is breast-feeding. There are standard pregnancy&#xD;
             procedures for use of radiopharmaceuticals in research at MGH.&#xD;
&#xD;
          7. Subject has experienced any allergic reaction to similar radiofluorinated compounds or&#xD;
             agents.&#xD;
&#xD;
        CORONARY ARTERY DISEASE (CAD) SUBJECTS&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must provide written informed consent prior to any study related procedures;&#xD;
&#xD;
          2. Subjects must be ≥ 20 and ≤ 80 years of age;&#xD;
&#xD;
          3. Subjects must have history of CAD documented by an abnormal stress myocardial&#xD;
             perfusion imaging (MPI) study and cardiac catheterization within 6 months of the BFPET&#xD;
             studyExclusion Criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a Positive (+) Serum and/or Urine Pregnancy Test or is lactating, or the&#xD;
             possibility of pregnancy cannot be ruled out prior to dosing;&#xD;
&#xD;
          2. Any clinically significant acute or unstable physical or psychological disease judged&#xD;
             by the investigators based on medical history or screening physical examination;&#xD;
&#xD;
          3. Coronary artery bypass graft (CABG) within 6 months;&#xD;
&#xD;
          4. Percutaneous coronary intervention (PCI), with stent placement within six months;&#xD;
&#xD;
          5. Blood pressure over 180/100;&#xD;
&#xD;
          6. Acute changes in ECG;&#xD;
&#xD;
          7. Recent (within 3 months) cardiac arrest, unstable angina, myocardial infarction,&#xD;
             cerebro-vascular accident (CVA), any general anesthesia procedure, any surgical&#xD;
             procedures;&#xD;
&#xD;
          8. Any implanted pacemaker or defibrillator use within the last three months;&#xD;
&#xD;
          9. Inability to remain in camera for approximately 60 minutes (Smokers and COPD are&#xD;
             included as long as they can breath in PET camera and not taking O2 through nasal&#xD;
             canula);&#xD;
&#xD;
         10. History of Diabetes Mellitus;&#xD;
&#xD;
         11. Serum creatinine &gt; 2 mg/dL;&#xD;
&#xD;
         12. All cancer patients;&#xD;
&#xD;
         13. Body Mass Index (BMI) is over 35;&#xD;
&#xD;
         14. Any exposure to any investigational drugs or medical device within four (4) weeks&#xD;
             prior to imaging study;&#xD;
&#xD;
         15. Any exposure to radiopharmaceuticals within four (4) weeks prior to the date of&#xD;
             imaging study;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Gewirtz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2008</study_first_posted>
  <last_update_submitted>June 6, 2013</last_update_submitted>
  <last_update_submitted_qc>June 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BFPET</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Myocardial Perfusion Imaging</keyword>
  <keyword>Radiation Dosimetry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

